about
Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).Methyl trypsin loaded poly(D,L-lactide-coglycolide) nanoparticles for contact lens care.Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy.Validation of a device for transcorneal drug permeation measure.Development of a liquid enzyme-based ceruminolytic product.Stability and ocular tolerance of cyclophosphamide-loaded nanospheresPreparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasoundDevelopment of Pranoprofen Loaded Nanostructured Lipid Carriers to Improve Its Release and Therapeutic Efficacy in Skin Inflammatory DisordersAn inductively coupled plasma method for determination of cyclophosphamide loaded to polymeric systemsAn investigation of FB interactions with poly(ethylene glycol) 6000, poly(ethylene glycol) 4000, and poly-epsilon-caprolactone by thermoanalytical and spectroscopic methods and modelingFlurbiprofen-loaded nanospheres: analysis of the matrix structure by thermal methodsImproved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogelsOptimizing flurbiprofen-loaded NLC by central composite factorial design for ocular deliveryPotential use of nanostructured lipid carriers for topical delivery of flurbiprofenStability and in vitro drug release of flurbiprofen-loaded poly-epsilon-caprolactone nanospheresCyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods
P50
Q33663056-18603BF1-D79E-4F41-AA6B-EEBB3F9B16CAQ43251301-F7BA6B97-ABC9-4B3E-AA53-3F84AB7475E6Q43272629-AD2C9D99-110B-45FB-AFC7-90CB9EA8FBF3Q44980687-138917EA-A880-48ED-B0FB-70A5C245452CQ46389274-F03D28BE-CE30-498D-82A9-88DD6DAEDC44Q46693276-B6571673-D133-4AF7-8C21-7FA835190AFFQ57378101-51B6A5B5-2277-4989-802A-5A4562EDDDFCQ59041627-CF2BA9C4-9BDA-44B0-AAB2-D7781AEF5116Q60910388-5D7BA4CF-5317-461D-8E9B-408205890CD9Q73507921-5D6E7C1B-80FE-4359-85EF-07F288F0F19CQ74511140-1D6C071D-86BE-4B60-811A-C1CF4FADFFB1Q74533966-C7E72CC1-E38F-43BA-9473-2A7F3B70E65BQ82107013-F9DDBBDA-B0DD-4CE2-938F-46649DDE2C13Q82949737-E0EB1517-C8E5-4279-B87A-27444FA65754Q84469598-CE5F2F85-44EC-4914-A626-7CA240DFCD1CQ93926969-8F9C2575-C48C-4778-B4EA-0B37E2C138A5Q94054864-64B0D37F-EE92-4CA7-B720-1CE5CC5B179B
P50
description
researcher ORCID ID = 0000-0002-4526-3344
@en
name
María L García
@ast
María L García
@en
María L García
@es
María L García
@nl
type
label
María L García
@ast
María L García
@en
María L García
@es
María L García
@nl
prefLabel
María L García
@ast
María L García
@en
María L García
@es
María L García
@nl
P214
P1153
7404277341
P1580
P214
P31
P496
0000-0002-4526-3344
P7859
viaf-306349283